Straits Times Index
3,140.21 +2.67 (+0.09%) S&P 500
3,862.99 -37.12 (-0.95%) Dow
31,256.48 -181.78 (-0.58%) Nasdaq
11,325.23 -199.33 (-1.73%) BTC-USD
20,734.07 -20.56 (-0.10%) CMC Crypto 200
451.15 +1.09 (+0.24%)
Gilead Sciences, Inc. (GILD)
| Previous close | 62.83 |
| Open | 62.83 |
| Bid | 62.72 x 800 |
| Ask | 62.74 x 800 |
| Day's range | 62.62 - 63.49 |
| 52-week range | 57.17 - 74.12 |
| Volume | |
| Avg. volume | 8,221,653 |
| Market cap | 78.639B |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 17.51 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.92 (4.65%) |
| Ex-dividend date | 14 Jun 2022 |
| 1y target est | N/A |
- Business Wire
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
SANTA MONICA, Calif., June 28, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Yescarta has maintained orphan medicinal product designation in this indication.
- Business Wire
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
FOSTER CITY, Calif., June 27, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.
- Business Wire
Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
FOSTER CITY, Calif., June 27, 2022--Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government Meeting (CHOGM), at a high-level session that was attended by Heads of State, other global dignitaries, industry partners and global community as part of a joint malaria and NTDs Summit. This high-level political declara
